Immunohistochemical biomarkers are prognostic relevant in
addition to the ESMO-ESGO-ESTRO risk classification in
endometrial cancer

J 2021

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

VREDE, S. W., W. J. VAN WEELDEN, N. C. M. VISSER, J. BULTEN, L. J. M. VAN DER PUTTEN et. al.

Základní údaje

Originální název

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

Autoři

VREDE, S. W., W. J. VAN WEELDEN, N. C. M. VISSER, J. BULTEN, L. J. M. VAN DER PUTTEN, K. VAN DE VIJVER, M. SANTACANA, E. COLAS, A. GIL-MORENO, C. P. MOIOLA, G. MANCEBO, C. KRAKSTAD, J. TROVIK, I. S. HALDORSEN, J. HUVILA, M. KOSKAS, Vít WEINBERGER (203 Česká republika, domácí), Markéta BEDNAŘÍKOVÁ (203 Česká republika, domácí), Jitka HAUSNEROVÁ (203 Česká republika, domácí), A. A. VAN DER WURFF, X. MATIAS-GUIU, F. AMANT, M. P. L. M. SNIJDERS, H. V. N. KUSTERS-VANDEVELDE, C. REIJNEN a J. M. A. PIJNENBORG

Vydání

Gynecologic Oncology, SAN DIEGO, ACADEMIC PRESS INC ELSEVIER SCIENCE, 2021, 0090-8258

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.304

Kód RIV

RIV/00216224:14110/21:00123112

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.ygyno.2021.03.031

UT WoS

000654681200023

Klíčová slova anglicky

Endometrial carcinoma; Immunohistochemistry; Biomarker; Outcome; Lymph node metastasis

Štítky

14110212, 14110230, 14110411, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 12. 2021 08:32, Mgr. Tereza Miškechová

Anotace

V originále

Objective. Pre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer (EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMOESGO-ESTRO risk classification and lymph node (LN) status in EC. Methods. Retrospective multicenter study within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), analyzing pre-operative IHC expression of p53, L1 cell-adhesion molecule (L1CAM), estrogen receptor (ER) and progesterone receptor (PR), and relate to ESMO-ESGO-ESTRO risk groups, LN status and outcome. Results. A total of 763 EC patients were included with a median follow-up of 5.5-years. Abnormal IHC expression was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER-in 76 (10.0%), and PR-in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the 'high and advanced/metastatic' risk group. In multivariate analysis p53-abn, ER/PR-and ESMO-ESGO-ESTRO 'high and advanced/metastatic' were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. Conclusion. The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/ PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorporation into the ESMO-ESGO-ESTRO risk classification. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/). sion was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER- in 76 (10.0%), and PR- in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the 'high and advanced/metastatic' risk group. In multivariate analysis p53-abn, ER/PR- and ESMO-ESGO-ESTRO 'high and advanced/metastatic' were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. Conclusion. The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/ PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorpora

Citovat

VREDE, S. W., W. J. VAN WEELDEN, N. C. M. VISSER, J. BULTEN, L. J. M. VAN DER PUTTEN, K. VAN DE VIJVER, M. SANTACANA, E. COLAS, A. GIL-MORENO, C. P. MOIOLA, G. MANCEBO, C. KRAKSTAD, J. TROVIK, I. S. HALDORSEN, J. HUVILA, M. KOSKAS, Vít WEINBERGER, Markéta BEDNAŘÍKOVÁ, Jitka HAUSNEROVÁ, A. A. VAN DER WURFF, X. MATIAS-GUIU, F. AMANT, M. P. L. M. SNIJDERS, H. V. N. KUSTERS-VANDEVELDE, C. REIJNEN a J. M. A. PIJNENBORG. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecologic Oncology. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2021, roč. 161, č. 3, s. 787-794. ISSN 0090-8258. Dostupné z: https://dx.doi.org/10.1016/j.ygyno.2021.03.031.

@article{1807759,
   author = {Vrede, S. W. and van Weelden, W. J. and Visser, N. C. M. and Bulten, J. and van der Putten, L. J. M. and van de Vijver, K. and Santacana, M. and Colas, E. and GilandMoreno, A. and Moiola, C. P. and Mancebo, G. and Krakstad, C. and Trovik, J. and Haldorsen, I. S. and Huvila, J. and Koskas, M. and Weinberger, Vít and Bednaříková, Markéta and Hausnerová, Jitka and van der Wurff, A. A. and MatiasandGuiu, X. and Amant, F. and Snijders, M. P. L. M. and KustersandVandevelde, H. V. N. and Reijnen, C. and Pijnenborg, J. M. A.},
   article_location = {SAN DIEGO},
   article_number = {3},
   doi = {http://dx.doi.org/10.1016/j.ygyno.2021.03.031},
   keywords = {Endometrial carcinoma; Immunohistochemistry; Biomarker; Outcome; Lymph node metastasis},
   language = {eng},
   issn = {0090-8258},
   journal = {Gynecologic Oncology},
   title = {Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S0090825821002699?via%3Dihub},
   volume = {161},
   year = {2021}
}

TY  - JOUR
ID  - 1807759
AU  - Vrede, S. W. - van Weelden, W. J. - Visser, N. C. M. - Bulten, J. - van der Putten, L. J. M. - van de Vijver, K. - Santacana, M. - Colas, E. - Gil-Moreno, A. - Moiola, C. P. - Mancebo, G. - Krakstad, C. - Trovik, J. - Haldorsen, I. S. - Huvila, J. - Koskas, M. - Weinberger, Vít - Bednaříková, Markéta - Hausnerová, Jitka - van der Wurff, A. A. - Matias-Guiu, X. - Amant, F. - Snijders, M. P. L. M. - Kusters-Vandevelde, H. V. N. - Reijnen, C. - Pijnenborg, J. M. A.
PY  - 2021
TI  - Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer
JF  - Gynecologic Oncology
VL  - 161
IS  - 3
SP  - 787-794
EP  - 787-794
PB  - ACADEMIC PRESS INC ELSEVIER SCIENCE
SN  - 00908258
KW  - Endometrial carcinoma
KW  - Immunohistochemistry
KW  - Biomarker
KW  - Outcome
KW  - Lymph node metastasis
UR  - https://www.sciencedirect.com/science/article/pii/S0090825821002699?via%3Dihub
N2  - Objective. Pre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer (EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMOESGO-ESTRO risk classification and lymph node (LN) status in EC. Methods. Retrospective multicenter study within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), analyzing pre-operative IHC expression of p53, L1 cell-adhesion molecule (L1CAM), estrogen receptor (ER) and progesterone receptor (PR), and relate to ESMO-ESGO-ESTRO risk groups, LN status and outcome. Results. A total of 763 EC patients were included with a median follow-up of 5.5-years. Abnormal IHC expression was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER-in 76 (10.0%), and PR-in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the 'high and advanced/metastatic' risk group. In multivariate analysis p53-abn, ER/PR-and ESMO-ESGO-ESTRO 'high and advanced/metastatic' were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. Conclusion. The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/ PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorporation into the ESMO-ESGO-ESTRO risk classification. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/). sion was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER- in 76 (10.0%), and PR- in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the 'high and advanced/metastatic' risk group. In multivariate analysis p53-abn, ER/PR- and ESMO-ESGO-ESTRO 'high and advanced/metastatic' were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. Conclusion. The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/ PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorpora
ER  -

VREDE, S. W., W. J. VAN WEELDEN, N. C. M. VISSER, J. BULTEN, L. J. M. VAN DER PUTTEN, K. VAN DE VIJVER, M. SANTACANA, E. COLAS, A. GIL-MORENO, C. P. MOIOLA, G. MANCEBO, C. KRAKSTAD, J. TROVIK, I. S. HALDORSEN, J. HUVILA, M. KOSKAS, Vít WEINBERGER, Markéta BEDNAŘÍKOVÁ, Jitka HAUSNEROVÁ, A. A. VAN DER WURFF, X. MATIAS-GUIU, F. AMANT, M. P. L. M. SNIJDERS, H. V. N. KUSTERS-VANDEVELDE, C. REIJNEN a J. M. A. PIJNENBORG. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. \textit{Gynecologic Oncology}. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE, 2021, roč.~161, č.~3, s.~787-794. ISSN~0090-8258. Dostupné z: https://dx.doi.org/10.1016/j.ygyno.2021.03.031.

Podrobný výpis o publikaci